Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
EXPLORE OUR SPECIALTIES BROWSE OUR TOPICS SUBSCRIBE TO RECEIVE UPDATES
Featured In Neuroscience
Developing Noninvasive Methods to Effectively Treat Complex Brain Disorders
Research at Massachusetts General Hospital combines advanced neuroimaging techniques and noninvasive brain stimulation to drive precision medicine for neurological disorders.
Featured In Ophthalmology
Mass Eye and Ear Ophthalmology: Celebrating 200 Years of Excellence in Patient Care, Research, and Education
This year, Mass Eye and Ear is celebrating its 200th anniversary. To kick things off, we are highlighting some of the ophthalmology department’s most significant achievements in patient care, research, and education.
Featured In Otolaryngology
CRISPR-Cas9 Genome Editing Treats Genetic Hearing Loss by Promoting Outer Hair Cell Survival
Yong Tao, PhD, Veronica Lamas, PhD, and Zheng-Yi Chen, DPhil, have extended their previous murine research to show CRISPR-associated protein 9 (Cas9)-based genome editing can treat hearing loss associated with monogenic mutations in outer hair cell genes and digenic mutations affecting both inner and outer hair cells.
Featured In Oncology
Developing a Personalized Approach for Targeted Radiotherapy of Liver Cancers
Researchers at Massachusetts General Hospital are developing computation models capable of increasing the precision of targeted delivery of radiotherapy to liver tumors.
Featured In Orthopaedics
Novel Model for Evaluation of Pain Treatments for Long-Bone Fracture
Massachusetts General Hospital orthopedic surgeons have developed a rat model in which gait and weightbearing are markers of recovery after repair of tibia fracture. Their long-term aim is to use the model to compare locally non-opioid analgesics to current pain management methods for long-bone fracture.
The Latest Oncology Advances
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Douglas M. Dahl, MD, Jason A. Efstathiou, MD, DPhil, and colleagues determined that in patients with muscle-invasive bladder cancer who were not candidates for cystectomy or cisplatin, maximum tumor resection and chemoradiation were associated with high response rates and five-year overall survival rates of 25% to 38%.
Comprehensive Lymphadenectomy Often Not Necessary in Surgical Management of Primary Endometrioid Ovarian Carcinoma
Varvara Mazina, MD, Marcela G. del Carmen, MD, MPH, and colleagues showed in a retrospective cohort of 63 women with primary endometrioid ovarian cancer that all pelvic and para-aortic lymph nodes removed were negative for carcinoma and comprehensive cancer staging had no effect on progression-free or overall survival.
Advances Specialties
Cardiovascular
Pathways Case Record: A Patient With Arteriovenous Malformations
A 68-year-old man with atrial fibrillation and recurrent melena was admitted with multiple episodes of dark, tarry stool and anemia. He was found to have small bowel arteriovenous malformations (AVMs). The Pathways Consult Service at Mass General investigated the etiology of this patient's gastrointestinal AVMs.
OB/GYN
Comprehensive Lymphadenectomy Often Not Necessary in Surgical Management of Primary Endometrioid Ovarian Carcinoma
Varvara Mazina, MD, Marcela G. del Carmen, MD, MPH, and colleagues showed in a retrospective cohort of 63 women with primary endometrioid ovarian cancer that all pelvic and para-aortic lymph nodes removed were negative for carcinoma and comprehensive cancer staging had no effect on progression-free or overall survival.
Ophthalmology
The Neuropeptide Alpha-Melanocyte–stimulating Hormone Prevents Persistent Corneal Edema After Injury
Reza Dana, MD, MSc, MPH; Jia Yin, MD, PhD, MPH; Ula V. Jurkunas, MD; and colleagues have discovered a critical role for neuropeptides in maintenance of corneal endothelial cells and potential therapeutic applications for α-melanocyte–stimulating hormone after corneal injury or intraocular surgery.
April 6-8, 2024
Conference: The American College of Cardiology's Annual Scientific Session & Expo
The American College of Cardiology (ACC) will host its Annual Scientific Session & Expo in Atlanta, GA, on April 6 – 8, 2024. ACC 2024 is your time to network with colleagues, see the latest science and innovation, and learn about practice-changing updates in care.
April 5-10, 2024
Conference: AACR Annual Meeting 2024
The 2024 American Association for Cancer Research (AACR) Annual Meeting brings together the best minds in cancer research to share the latest in cancer science and medicine. The Mass General Cancer Center is honored to join their international colleagues on April 5-10 in San Diego.